Case Reports of Acute Transverse Myelitis Associated With mRNA Vaccine for COVID-19

Acute transverse myelitis (ATM) has been reported as rare complication of vaccination. Herein, we report 2 cases of ATM after the administration of an mRNA vaccine for coronavirus disease 2019 (COVID-19). The first one is an 81-year-old man who received the BNT162b2 vaccine. He presented with bilate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2022, 37(7), , pp.1-5
Main Authors: Eom, Hyunjong, Kim, Seung Woo, Kim, Minkyoung, Kim, Ye Eun, Kim, Ji Hyun, Shin, Ha Young, Lee, Hye Lim
Format: Article
Language:English
Subjects:
Aged, 80 and over
BNT162 Vaccine - adverse effects
BNT162 Vaccine - immunology
Case Report
COVID-19 - immunology
Female
Hand - physiopathology
Humans
Leg - physiopathology
Magnetic Resonance Imaging
Male
Methylprednisolone - therapeutic use
Myelitis, Transverse - diagnosis
Myelitis, Transverse - drug therapy
Myelitis, Transverse - pathology
SARS-CoV-2 - immunology
Spinal Cord - physiopathology
Spine - diagnostic imaging
Vaccination - adverse effects
Young Adult
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute transverse myelitis (ATM) has been reported as rare complication of vaccination. Herein, we report 2 cases of ATM after the administration of an mRNA vaccine for coronavirus disease 2019 (COVID-19). The first one is an 81-year-old man who received the BNT162b2 vaccine. He presented with bilateral hand weakness. Spine magnetic resonance imaging (MRI) showed high signal intensity from the C1 to C3 vertebrae. The second is a 23-year-old woman who received the BNT162b2 vaccine and experienced tingling in her legs. Spine MRI showed a high signal intensity lesion at the conus medullaris. These patients were treated with intravenous methylprednisolone and their symptoms improved slightly. Careful follow-up is needed to identify adverse events after the administration of mRNA vaccines for COVID-19.
ISSN:1011-8934
1598-6357
1598-6357
DOI:10.3346/jkms.2022.37.e52